Professor Sir Peter Horby
Emerging infectious diseases
Research on emerging infectious diseases can only be conducted during outbreaks. Although virology has improved, a well calibrated and effective public health response is often lacking. Epidemiological and clinical research as well as mathematical modelling will give us answers during the epidemics and help us provide better diagnostics and better treatments.
Moh Family Foundation Professor of Emerging Infections and Global Health
- Director, Pandemic Sciences Institute
- Executive Director, ISARIC
PANDEMIC SCIENCES INSTITUTE
Sir Peter Horby is Moh Family Foundation Professor of Emerging Infections and Global Health at the University of Oxford and the Director of the Pandemic Sciences Institute. The Pandemic Sciences Institute is a multidisciplinary initiative to create collaborative science-driven solutions to identify, prepare for, and counter pandemic threats. He is also Executive Director of the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC), a consortium of international, national and local research networks whose research activities span 134 countries worldwide.
He is Co-Chief Investigator of the RECOVERY trial of treatments for viral pneumonia.
He has advised the World Health Organisation, the UK Government and other agencies on epidemic preparedness, clinical research and clinical trial design for epidemic infectious diseases.
He is the former, and founding, Director of the Oxford University Clinical Research Unit in Hanoi, Vietnam. The unit was established in early 2006 and conducts research on infectious diseases which crosses the disciplines of basic science, medical science and public health.
RECOVERY TRIALS RESULTS
EFFECT OF DEXAMETHASONE ON 28-DAY MORTALITY IN SEVERE COVID-19.
- Gail Carson
Tropical Medicine, Oxford University, NDM Research Building, United Kingdom
- Janet Scott
University of Glasgow, United Kingdom
Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.
Pairo-Castineira E. et al, (2023), Nature, 619
GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.
Pairo-Castineira E. et al, (2023), Nature, 617, 764 - 768
Seroepidemiology of Lassa virus in pregnant women in Southern Nigeria: A prospective hospital-based cohort study.
Kayem ND. et al, (2023), PLoS neglected tropical diseases, 17
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Horby PW. et al, (2023)
Transplacental transfer of Lassa IgG antibodies in pregnant women in Southern Nigeria: A prospective hospital-based cohort study.
Kayem ND. et al, (2023), PLoS Negl Trop Dis, 17